BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Akeso Showcases Positive Phase III Safety Run-In Data for Cadonilimab at SGO 2025 in Locally Advanced Cervical Cancer

Akeso Inc. (9926.HK) presented promising phase III safety run-in results from the COMPASSION-18/AK104-305 study, at the 2025 Annual Meeting of the Society ...

March 24, 2025 | Report

Menarini Group, Stemline, and VisualDx Join Forces to Boost Early Detection of BPDCN Using AI-Driven Skin Imaging

BPDCN is an aggressive hematologic malignancy with a historically poor prognosis VisualDx is a clinical decision support system used by more than 2,300 ...

March 21, 2025 | News

Telix Secures FDA Approval for Gozellix® to Expand PSMA-PET Imaging Access in Prostate Cancer

Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that the United States (U.S.) Food and Drug Administrat...

March 21, 2025 | News

Shanghai Henlius Secures FDA Orphan Drug Designation for HLX22 in Gastric Cancer

Shanghai Henlius Biotech, Inc. (2696.HK) announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for...

March 20, 2025 | News

Alphamab Oncology and CSPC’s Anti-HER2 ADC JSKN003 Secures Breakthrough Therapy Designation in China

Alphamab Oncology (stock code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. ("CSPC") (Stock Code: 1093.HK) jointly announced that anti-HER2 biparatopic...

March 19, 2025 | News

Lunit Secures Multi-Year AI Partnership with SEHA to Advance Breast Cancer Screening in UAE

Lunit , a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, announced that it has signed a multi-year contract with Abu Dha...

March 19, 2025 | News

Exicure Secures Australian Patent for Dual-Target Cancer Therapy Approach

Exicure, Inc. announced that the Australian Patent Office has issued Patent No. 2018388302, titled "GPCR Heteromer Inhibitors and Uses Thereof." ...

March 14, 2025 | News

Celltrion Launches STEQEYMA®, a Biosimilar to STELARA®, in the U.S. at an 85% Lower WAC List Price

STEQEYMA®, one of the first-wave biosimilars to STELARA®, is now available in the U.S. Approved for the same indications as the reference produc...

March 13, 2025 | News

Gleneagles Hospital Hong Kong Becomes Asia’s First Private Hospital to Offer Histotripsy for Liver Cancer Treatment

Gleneagles Hospital Hong Kong (Gleneagles) is excited to be the first private hospital in Asia to offer Histotripsy treatment, the transformative...

March 11, 2025 | News

South Korea’s Lunit AI Proven to Enhance Breast Cancer Detection in Landmark Multicenter Study

Lunit, a global leader in AI-powered cancer diagnostics, has announced groundbreaking results from the world’s first large-scale, multicenter, prospe...

March 11, 2025 | News

Everest Medicines Doses First Patient with AI-Driven Personalized mRNA Cancer Vaccine EVM16 in Landmark Clinical Trial

The first patient has been dosed with EVM16 at Peking University Cancer Hospital, marking a major milestone as Everest's proprietary AI-based tumor neoan...

March 07, 2025 | News

CStone Pharmaceuticals Advances CS5001 with Phase Ib Trial Application in Australia for First-Line DLBCL Treatment

Phase Ib trial to evaluate CS5001 in combination with R-CHOP as a first-line treatment for diffuse large B-cell lymphoma (DLBCL), aiming to reshape ...

March 06, 2025 | News

CStone Pharmaceuticals Doses First Patient in Global Phase I Trial of Trispecific Antibody CS2009

CStone Pharmaceuticals ("CStone", HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of anti-cancer therap...

March 05, 2025 | News

Daiichi Sankyo and AstraZeneca’s ENHERTU Recommended for EU Approval for HER2 Low and HER2 Ultralow Metastatic Breast Cancer

Daiichi Sankyo (TSE: 4568) and AstraZeneca’s (LSE/STO/Nasdaq: AZN) ENHERTU® (trastuzumab deruxtecan) has been recommended for approval in th...

March 03, 2025 | News

Stay Connected